KRYS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Krystal Biotech Inc (KRYS) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company has strong financial performance, consistent analyst support with increasing price targets, and a promising pipeline. Despite neutral trading sentiment and no significant technical breakout, the long-term growth potential outweighs short-term fluctuations.
The MACD is positive and expanding, indicating a bullish momentum. RSI is neutral at 46.294, and moving averages are converging, suggesting no clear trend. Key support is at 245.045, and resistance is at 260.76. The stock is trading near its pivot point of 252.903, showing consolidation.
Strong financial performance in Q4 2025, with revenue up 17.52% YoY and net income up 13.02% YoY.
Analysts consistently raising price targets, with the highest target at $
Promising pipeline with key catalysts in 2026, including KB801/803 and KB
Vyjuvek sales growth and international expansion potential.
Neutral sentiment from hedge funds and insiders.
Slight decline in gross margin (-0.76% YoY).
No significant recent congress trading data or influential figure activity.
In Q4 2025, Krystal Biotech reported revenue growth of 17.52% YoY to $107.1M, net income growth of 13.02% YoY to $51.4M, and EPS growth of 11.84% YoY to $1.7. However, gross margin slightly declined to 93.85%, down 0.76% YoY.
Analysts are overwhelmingly positive, with multiple Buy ratings and price targets raised recently. The highest price target is $371, reflecting confidence in the company's growth trajectory and pipeline progress. Wolfe Research initiated coverage with a Peer Perform rating, citing fair valuation but cautious optimism about upcoming catalysts.
